Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
GAINESVILLE, Fla., Jan. 06, 2016 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, and San Antonio-based Fountainhead Investment Partners announced today a $689,000 infusion to close AmnioLife’s Series A Round. The Series A financing totaled $1.5 million with Fountainhead leading the investment round, contributing $1.4 million of the capital.
|
|||
“2015 was a successful year for AmnioLife with the launch of our human DBM product line, the patent for our collagen membrane preservation process and the addition of key staff. Closing the Series A Round supports commercialization and manufacturing of our products to set the foundation for growth in 2016,” said Chris Broderick, AmnioLife CEO.
AmnioLife will utilize the capital to expand and enhance its existing product portfolio and to support additional manufacturing initiatives related to its osteobiologics product portfolio launched in the fourth quarter of 2015.
“When we founded Fountainhead Investment Partners, we had companies like AmnioLife in mind,” said Brian Kieser, Fountainhead Managing Partner. “The company is focused on innovation but at the same time is positioned for commercialization that with our support and investment can accelerate the path to success.”
Fountainhead Investment Partners is focusing its initial investments in areas of medical devices, surgical tools, multicellular biologics, regenerative technologies, medical knowledge management and 3D printing. Investments ranging from $250,000 to $1.5 million will be made in early-stage companies with the vision of connecting advancing technologies in order to solve some of medicines' most complex issues.
About AmnioLife
AmnioLife is a research and development organization focused on placental-derived technologies with a GxP manufacturing program at its Gainesville, Fla. facility. AmnioLife is developing a strong IP-position for advanced biologic products and has commercialized a suite of minimally manipulated tissue products that are sold through established global sales channel partners. For more information, visit http://www.amniolife.com.
About Fountainhead Investment Partners
Fountainhead Investment Partners is a venture capital firm, based in San Antonio, Texas, that invests in early-stage companies. Fountainhead was originally founded as an angel fund in 2014 by a group of successful healthcare entrepreneurs with a vision to connect advancing technologies in order to solve some of medicines’ most complex issues.
In 2015, Fountainhead transitioned to a venture capital firm, with initial funds focused on companies that are accessing innovative technologies from all industries and applying them to the science of medicine with the intention of disrupting the industry while also advancing patient care.
Fountainhead makes portfolio investments ranging from $250,000 to $1.5 million. Partners work side-by-side with portfolio companies on operations strategies and management guidance in order to maximize the highest potential growth.
Bonnie Caver
512-832-8588
